AXSM News and Press, Axsome Therapeutics Inc. From 03/09/23

2023-03-09 14:52:53 ET Summary Given that Axsome Therapeutics, Inc. is launching Auvelity with a small in-house team, you can expect a substantial sales increase in the next three years. In a highly favorable deal, Axsome recently out-licensed its ex-USA rights of Sunosi to Pharma...

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Off...

Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q4 2022 Earnings Call Feb 27, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Axsome Therapeutics (AXSM) Q4 2022 Earnings Call Transcript

The US FDA has asked Axsome Therapeutics ( NASDAQ: AXSM ) to provide additional long-term safety data and information for AXS-05, its late-stage asset for Alzheimer's disease agitation. The agency wrote that the company should provide placebo-controlled safety information from the ong...

Axsome Therapeutics, Inc. (AXSM) Q4 2022 Earnings Conference Call February 27, 2023 08:00 AM ET Company Participants Mark Jacobson - COO Herriot Tabuteau - Chairman & CEO Nick Pizzie - CFO Lori Englebert - EVP, Commercial and Business Development Hunter Mur...

Axsome Therapeutics press release ( NASDAQ: AXSM ): Q4 GAAP EPS of -$1.41 misses by $0.28 . Revenue of $24.37M beats by $2.49M . Auvelity was launched on October 19, 2022 and had U.S. net sales of $5.2 million for the fourth quarter of 2022. No Auvelity sales...

Total fourth quarter net product sales of $24.4 million Auvelity ® launched October 19th, with fourth quarter net product sales of $5.2 million Sunosi ® fourth quarter net product sales of $19.2 million Sunosi ® license ...

Axsome Therapeutics ( NASDAQ: AXSM ) is scheduled to announce Q1 earnings results on Monday, February 27th, before market open. The consensus EPS Estimate is -$1.13 (-9.7% Y/Y) and the consensus Revenue Estimate is $21.88M Over the last 1 year, AXSM has beaten EPS estimates ...

Axsome Therapeutics ( NASDAQ: AXSM ) announced a licensing agreement with U.K.-based Pharmanovia on Wednesday for Sunosi, a medication indicated in Europe for excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). Per the terms, Pharmanovia wil...

Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical studies in Europe and MENA NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Axsome T...